MK-677 vs sermorelin: how the two actually compare

Last updated 2026-07-25

What are MK-677 and sermorelin, and how are they different drugs?

Sermorelin is a synthetic fragment of growth hormone-releasing hormone (GHRH), the first 29 amino acids of the natural 44-amino-acid hormone. It binds the GHRH receptor on the pituitary and tells the pituitary to make and release its own growth hormone. It's a peptide, given by injection, and it mimics a hormone your body already produces. MK-677, also called ibutamoren, is a completely different kind of molecule. It's a small, non-peptide organic compound taken by mouth that acts on the ghrelin receptor (the growth hormone secretagogue receptor), a separate pathway from GHRH that also drives GH release. It was developed in the 1990s as a potential treatment for GH deficiency and frailty, but it never made it through FDA approval and isn't sold as an approved drug anywhere in the US. Both compounds raise growth hormone by working upstream of the pituitary, not by replacing GH directly the way injectable HGH (somatropin) does. That's the one thing they share. Everything else, chemistry, route, regulatory status, safety data, differs quite a bit. A recent review in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews looked at therapeutic peptides used in orthopedic and musculoskeletal contexts, and it treats these GH-axis peptides as a class worth watching but flags real gaps in how they've been studied outside narrow clinical indications ^[1]. For readers weighing sermorelin specifically against injectable HGH rather than MK-677, our companion piece on sermorelin injection sites covers the practical mechanics of getting started.

MK-677 vs sermorelin: regulatory status side by side

This is the part most comparison articles skip, and it's the most concrete difference between the two. Sermorelin has an actual FDA history. It was approved and marketed in the US under the brand name Geref for diagnosing and treating growth hormone deficiency. The branded product was later discontinued, which matters because discontinued is not the same as withdrawn for safety. Companies discontinue drugs for commercial reasons (low sales, manufacturing costs, better alternatives on the market) all the time. You can confirm approval history for any drug, including whether a product is listed as discontinued versus withdrawn, through the FDA's own Drugs@FDA database ^[2]. Today, sermorelin used in the US is not sold as an FDA-approved finished drug. It's available through compounding pharmacies, which operate under a different legal framework than manufacturers of FDA-approved drugs. Compounders working under 21 U.S.C. 353a can prepare drugs from bulk substances for individual patients under specific conditions ^[3], and FDA maintains lists of bulk substances that can (21 CFR 216.23) or cannot be used this way for 503A pharmacies, with a parallel list for 503B outsourcing facilities under 21 CFR 216.24 ^[4][5]. Sermorelin's compounding status has moved around on FDA's nominated bulk substances list over the years, so anyone sourcing it should check the current list rather than assume permanent status ^[6]. MK-677 has none of this history. It has never been an FDA-approved drug for any indication, human or otherwise. It's sold online as a "research chemical," which is a legal gray zone, not a regulatory pathway. There's no Geref-style approval, no discontinued-brand paper trail, nothing in Drugs@FDA. That absence of history is itself informative: it means the manufacturing quality control, dosing standardization, and adverse-event reporting infrastructure that comes with FDA oversight simply doesn't exist for MK-677 the way it briefly did for sermorelin. If you're trying to figure out where sermorelin itself can be sourced legitimately, see our guide on the best place to buy sermorelin.

How do MK-677 and sermorelin actually work in the body?

Sermorelin works through the GHRH receptor. It stimulates the pituitary's own machinery to synthesize and pulse-release growth hormone, which means it depends on having a pituitary that still works. If someone's pituitary somatotroph cells are damaged or absent, sermorelin won't do much, because there's nothing left to stimulate. MK-677 works through the ghrelin/growth hormone secretagogue receptor, a separate receptor system that also increases GH pulses but through a different signaling route, and it has a much longer half-life than sermorelin, which is part of why it can be dosed once daily by mouth rather than by injection. Both ultimately raise IGF-1, the downstream marker doctors actually track to see if GH signaling increased. A study in hypogonadal men treated with a growth hormone secretagogue found it raised serum IGF-1 levels significantly compared to placebo ^[7], and a related paper on secretagogues in hypogonadal males looked at body composition outcomes in this population specifically, not in healthy adults chasing performance gains ^[8]. That distinction matters: nearly all of the more rigorous secretagogue data exists in deficiency or hypogonadism populations, not in otherwise healthy people looking for an edge.

MK-677 vs sermorelin: dosing, route, and daily experience

Route of administration is the most obvious practical difference. Sermorelin is injected, typically subcutaneously, usually once daily, often at night to work with the body's natural nocturnal GH pulse. If you want the mechanics of where and how those injections are given, see sermorelin injection sites. MK-677 is a pill or liquid taken orally, once a day, no needles involved. For someone who's needle-averse, that's a real convenience difference, and it's probably the single biggest reason MK-677 gets discussed as an "easier" option online. But convenience isn't the same as being a better-supported choice. Sermorelin's dosing history comes out of actual clinical development work, including its historical use in children with GH deficiency, which was reviewed in a 1999 BioDrugs paper describing its role in both diagnosis and treatment of pediatric GH deficiency ^[9]. MK-677's dosing in humans mostly comes from smaller trials run during its original (abandoned) drug development program plus whatever protocols have circulated informally since. There's no equivalent depth of dose-ranging data behind the doses commonly used online today. For a closer look at how sermorelin doses are actually structured in practice, see our guide on sermorelin clinical trials.

Which one has better safety and side effect data?

Sermorelin's side effect profile is reasonably well characterized because it went through actual drug development and was studied in adults with GH insufficiency. A 2006 review in Clinical Interventions in Aging examined sermorelin specifically for adult-onset GH insufficiency and discussed it as a physiologic approach, meaning it works within the body's own feedback loops rather than overriding them ^[10]. Because sermorelin only stimulates the pituitary rather than delivering GH directly, the body's own negative feedback can still limit runaway GH or IGF-1 levels, at least in theory. This is the main safety argument for GHRH analogs over exogenous GH. MK-677 doesn't have that same protective ceiling. It also has some documented side effects even in study settings, including increased appetite, fluid retention, and effects on insulin sensitivity, which is part of why it never cleared the approval bar for the indications it was tested against. Because it isn't a regulated pharmaceutical product now, the actual material people buy online varies in purity and labeling, and problems with counterfeit or falsified injectable biopharmaceuticals have been documented in Europe, which is a caution about the supply chain around unregulated injectables and peptides generally, not proof about any specific MK-677 product ^[11]. Neither drug has anything close to the long-term safety data of decades of clinical use in large populations. What's genuinely different is that sermorelin's known risks were characterized during an actual FDA drug development and approval process, and MK-677's were characterized during a development process that stopped short of approval.

Is MK-677 legal? Is sermorelin legal?

Sermorelin's legal status runs through the compounding pharmacy framework. A licensed pharmacy can legally prepare sermorelin for a patient with a valid prescription, under the rules in 21 U.S.C. 353a for traditional (503A) compounders, provided the bulk substance is on FDA's permitted list under 21 CFR 216.23, or under 21 CFR 216.24 for 503B outsourcing facilities ^[3][4][5]. That's a real, if narrower, legal pathway, and it requires a prescriber. MK-677 is typically sold labeled "not for human consumption" or "research use only," which is a legal fiction sellers use to sidestep drug regulation, not a real research designation. There's no FDA-sanctioned pathway for a pharmacy to compound and dispense MK-677 to a patient the way there is for sermorelin, because MK-677 isn't a peptide hormone drug substance moving through that same bulk-substances framework in the same way. Buying it online puts the burden of quality control entirely on the seller's word, with none of the oversight a prescription and pharmacy relationship provides.

MK-677 vs sermorelin vs HGH: how do all three compare?

This is really the central question most people researching sermorelin actually want answered: how does it stack up against HGH itself, and where does MK-677 fit? HGH (somatropin) is the hormone itself, given by injection, and it's FDA-approved for specific indications like confirmed adult and pediatric GH deficiency, and it directly raises GH and IGF-1 regardless of whether your pituitary works. Sermorelin only works if your pituitary can still respond, and it produces a smaller, more physiologic rise in GH because your body's own feedback loops stay intact. That's a real limitation: sermorelin is the weaker option for someone who needs a guaranteed, large, and predictable increase in GH, which is why HGH remains the standard for confirmed adult GH deficiency and sermorelin has a narrower practical role today. MK-677 sits somewhere between, mechanistically, but without HGH's approval history or sermorelin's approval history. It's an oral secretagogue with no finished-drug approval anywhere.

Does MK-677 or sermorelin help with muscle, fat loss, or athletic performance?

Neither drug has solid evidence supporting use for muscle gain, fat loss, or athletic performance in healthy adults, and this article isn't going to pretend otherwise. A 2026 review in Sports Medicine examined the safety and efficacy evidence for both approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, and the framing itself, approved versus unapproved, signals how much of what's marketed for performance sits outside real evidence ^[12]. A separate 2026 review in Frontiers in Endocrinology specifically looked at the gap between clinical evidence and the reality of patients self-administering GH-IGF1 axis peptides for performance, describing that gap as an emerging concern rather than a settled, evidence-backed practice ^[13]. Growth hormone secretagogues, including both GHRH analogs like sermorelin and ghrelin-receptor agonists like MK-677, are banned in competitive sport, and anti-doping labs have built out fairly serious detection methods for GHRH analogs specifically, including mass spectrometry methods for urine and plasma ^[14][15][16]. That level of analytical effort exists because these compounds get used for performance purposes despite the approval gap, not because there's a body of evidence proving they work for that purpose in healthy people.

What does the research actually say sermorelin is good for?

Sermorelin's clearest, best-supported use case is diagnosing and treating confirmed growth hormone deficiency, particularly the pediatric population it was originally studied in. The 1999 BioDrugs review covers its use for diagnosing idiopathic GH deficiency in children as well as treatment ^[9], and the 2006 Clinical Interventions in Aging paper extends the discussion to adult-onset GH insufficiency, framing sermorelin as a physiologic alternative to direct GH replacement for some patients ^[10]. Outside of that core indication, sermorelin shows up in more exploratory research. A 2021 paper in Annals of Translational Medicine explored sermorelin as a potentially effective drug for patients with recurrent glioma, which is an early, mechanism-driven hypothesis, not an established treatment use, and shouldn't be read as sermorelin being an approved or proven cancer therapy ^[17]. There's also older physiology research, including a 1990 study in the Journal of Clinical Endocrinology and Metabolism, looking at how GH-releasing factor affects maternal and fetal pituitary and placental GH secretion during pregnancy, which is basic endocrine physiology work, not a clinical protocol ^[18]. The throughline across the legitimate literature is narrow: sermorelin's strongest evidence sits in GH deficiency diagnosis and treatment, not in general wellness, performance, or anti-aging use.

How much does each option cost, and where do you get them?

Sermorelin, sourced through a licensed compounding pharmacy with a prescription, typically runs in the range clinics quote for monthly compounded peptide therapy, though exact pricing varies by pharmacy, dose, and region, and there's no single official price list to cite here, so ask any clinic for their current compounding pharmacy quote before assuming a number. What you're paying for includes the pharmacy's compliance with 503A or 503B rules, batch testing, and a prescriber relationship, more than the raw peptide. MK-677 is sold online, unregulated, often cheaper per unit than compounded sermorelin, but with zero verification of what's actually in the vial or capsule, no prescriber oversight, and no legal recourse if the product is mislabeled or contaminated. Reports of falsified biopharmaceutical injectables circulating in unregulated markets in Europe are a real documented problem in this space ^[11], and it's a reasonable reason to be skeptical of unregulated peptide and secretagogue sellers generally. If you're going the sermorelin route, the honest answer is: don't buy it directly from a website with no prescriber involved. Go through a legitimate telehealth or clinic pathway that requires labs and a prescription, and use a pharmacy that's actually licensed under 503A or 503B rules. For a practical breakdown of what a legitimate sourcing path looks like, see best place to buy sermorelin.

Who should actually consider sermorelin over MK-677 (or neither)?

If you have documented, lab-confirmed growth hormone deficiency, sermorelin is worth discussing with an endocrinologist or a prescriber experienced with GH-axis therapy, precisely because it has real regulatory and clinical history behind it, including its former FDA-approved life as Geref ^[2][10]. That history means more is known about typical response, typical side effects, and how it fits into a monitored treatment plan. If you're a healthy adult chasing muscle, better sleep, fat loss, or general "optimization" with no diagnosed deficiency, be honest with yourself: neither sermorelin nor MK-677 has strong evidence supporting that use, and MK-677 in particular carries the added risk of having never gone through FDA review for any indication. The Sermorelin Co editorial position on this is straightforward: sermorelin only makes sense as part of a provider-reviewed plan with labs before and during treatment, sourced through a pharmacy that's actually accountable, not as a self-directed purchase from an unregulated seller. MK-677 doesn't have that pathway available at all right now in the US.

What are the biggest open questions and unknowns?

Long-term safety data is thin for both compounds in the populations actually buying them online, which skew toward healthy adults rather than the GH-deficient patients these drugs were originally studied in. Nobody has good long-term outcome data on MK-677 use in healthy adults over years, and the honest answer is that it doesn't exist yet in any rigorous form. For sermorelin, the open questions are narrower: how it performs against modern compounded quality standards, what the right maintenance dose looks like outside the original Geref-era protocols, and how reliably compounded product matches what a pharmacy claims is in the vial. Analytical chemistry work on detecting GHRH analogs and related peptides in biological samples, including studies on their stability and degradation in serum, continues largely because anti-doping and forensic labs need better tools, which is itself a signal that verifying what's actually in a peptide product is a real, unresolved problem across this drug class, not a solved one ^[19][20].

Frequently asked questions

Is MK-677 the same as sermorelin?

No. Sermorelin is an injectable peptide fragment of GHRH that stimulates the pituitary through the GHRH receptor. MK-677 (ibutamoren) is an oral small molecule that stimulates GH release through the separate ghrelin receptor pathway. They raise growth hormone through different mechanisms and have very different regulatory histories in the US.

Is sermorelin FDA-approved?

Sermorelin was FDA-approved and marketed in the US under the brand name Geref. That branded product was later discontinued, which was a business decision, not a safety withdrawal. Today sermorelin is available in the US mainly through compounding pharmacies operating under 21 U.S.C. 353a, not as an approved finished drug product.

Is MK-677 FDA-approved?

No. MK-677 (ibutamoren) has never been approved by the FDA for any human or animal use. It was studied in development programs decades ago but never cleared approval, and it's currently sold online labeled as a research chemical, which has no legal standing as an approved or prescribable drug.

Which is safer, MK-677 or sermorelin?

Sermorelin has more documented clinical history because it went through actual FDA drug development as Geref and has been studied in adults with GH insufficiency. MK-677's side effects, including appetite changes and effects on insulin sensitivity, were documented in studies that stopped short of approval. Neither has strong long-term safety data in healthy adults using them outside diagnosed deficiency.

Can you take MK-677 and sermorelin together?

Some protocols combine a GHRH analog like sermorelin with a ghrelin-receptor agonist because they work through different receptors and can produce an additive rise in GH pulses. There's limited rigorous clinical trial data on this specific combination in healthy adults, and MK-677's unregulated sourcing adds risk on top of whatever benefit is claimed. Discuss any combination with a prescriber first.

Why was Geref (sermorelin) discontinued?

Geref was discontinued as a commercial product, not withdrawn for safety reasons. Drug manufacturers discontinue approved products for various business reasons, including low sales volume or shifts toward other GH-axis treatments. You can check a drug's approval and marketing status directly in FDA's Drugs@FDA database.

Does MK-677 build more muscle than sermorelin?

There isn't strong clinical evidence that either compound reliably builds muscle in healthy adults without diagnosed GH deficiency. Reviews of peptide use for musculoskeletal and athletic performance purposes describe this area as full of unapproved use outstripping the actual evidence, rather than confirming muscle-building benefits for either drug.

Is MK-677 legal to buy online in the US?

MK-677 is typically sold online labeled "research use only" or "not for human consumption," a labeling workaround rather than a genuine legal research designation. It has no FDA-sanctioned pathway for human use or pharmacy compounding the way sermorelin does under 503A and 503B rules, so buying it puts all quality and safety risk on the buyer.

How is sermorelin dosed compared to MK-677?

Sermorelin is typically injected subcutaneously once daily, often at bedtime to align with natural GH pulses. MK-677 is taken orally once daily due to its longer half-life. Sermorelin's dosing has real clinical development history behind it from its Geref-era studies; MK-677's common online dosing largely comes from smaller early trials and informal protocols.

Do MK-677 and sermorelin show up on drug tests or anti-doping tests?

Both are banned by anti-doping authorities, and analytical labs have built specific mass spectrometry methods to detect GHRH analogs like sermorelin in urine and plasma, and to standardize detection of related doping peptides. This detection work exists specifically because these compounds are used for performance purposes outside approved indications.

Which is better for someone with diagnosed growth hormone deficiency, sermorelin or MK-677?

Sermorelin has the stronger case here, since it has actual clinical history in GH deficiency, including pediatric use, and requires a functioning pituitary that a prescriber can confirm with testing. MK-677 lacks that approval history entirely. For confirmed deficiency, direct HGH replacement is often the standard rather than either secretagogue, depending on the case.

Is sermorelin weaker than HGH?

In terms of raw effect, yes. Sermorelin only stimulates your own pituitary to release GH, so it depends on pituitary function and produces a smaller, feedback-limited rise in GH and IGF-1 than injecting HGH directly. HGH bypasses that dependency entirely, which is why it remains the standard treatment for confirmed GH deficiency in many cases.

Sources

1. Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopedics discusses applications and evidence gaps for GH-axis peptides
2. FDA, Drugs@FDA database: Source for confirming a drug's approval history, including sermorelin's approval as Geref and its later discontinuation status
3. 21 U.S.C. 353a, pharmacy compounding: Legal framework under which 503A compounding pharmacies may prepare drugs like sermorelin for individual patients with a prescription
4. 21 CFR 216.23, the final 503A Bulks List: FDA's list of bulk drug substances permitted for use in compounding under section 503A
5. 21 CFR 216.24, the 503B Bulks List: FDA's parallel bulk substances list governing compounding by 503B outsourcing facilities
6. FDA, bulk drug substances nominated for use in compounding (current list): Sermorelin's compounding eligibility is subject to FDA's evolving nominated bulk substances list, not a permanent guarantee
7. American Journal of Men's Health, 2017 (PMID 28830317): Growth hormone secretagogue treatment in hypogonadal men significantly raised serum IGF-1 levels
8. Translational Andrology and Urology, 2020 (PMID 32257855): Review of growth hormone secretagogues for body composition management specifically in hypogonadal males
9. BioDrugs, 1999 (PMID 18031173): Review of sermorelin's use in diagnosing and treating idiopathic growth hormone deficiency in children
10. Clinical Interventions in Aging, 2006 (PMID 18046908): Review discussing sermorelin as a physiologic approach to managing adult-onset growth hormone insufficiency
11. Drug Testing and Analysis, 2016 (PMID 26456392): Documentation of falsified antibiotics and biopharmaceutical injectables circulating in unregulated markets in Europe
12. Sports Medicine, 2026 (PMID 41966639): Review of safety and efficacy evidence for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance
13. Frontiers in Endocrinology, 2026 (PMID 42395176): Review describing the gap between clinical evidence and patient self-administration of GH-IGF1 axis performance peptides
14. Drug Testing and Analysis, 2021 (PMID 34665524): Advances in analytical detection methods for GHRH synthetic analogs used in doping contexts
15. Journal of Mass Spectrometry, 2024 (PMID 38197510): Chromatographic-mass spectrometric methods developed for detecting peptidic analytes including GHRH analogs in doping control urine samples
16. Analytical and Bioanalytical Chemistry, 2016 (PMID 26879649): Immunoaffinity purification and mass spectrometry method developed to qualitatively identify GHRH in human plasma
17. Annals of Translational Medicine, 2021 (PMID 33842627): Exploratory paper proposing sermorelin as a potentially effective drug for patients with recurrent glioma
18. Journal of Clinical Endocrinology and Metabolism, 1990 (PMID 2143200): Physiology study on how GH-releasing factor affects maternal and fetal pituitary and placental GH secretion
19. Biomedical Chromatography, 2023 (PMID 37688464): Study of enzymatic and serum stability and degradation profiles of GHRP and GHRH-related peptides used as doping standards
20. Journal of Pharmaceutical and Biomedical Analysis, 2026 (PMID 41138283): Development of nano-LC and mass spectrometry methods to analyze GHRH and its analogs in urine samples